Merck, Bayer part of industry shakeup

Share this article:

While it may look like last week's GSK-Novartis deal left Merck without a consumer business suitor, this week's news indicates otherwise: the Wall Street Journal reports that Reckitt Benckiser confirmed it “was in talks” to pick up the consumer health business, which includes OTC products such as allergy medication Claritin, foot care line Dr. Scholl's and the Coppertone sunscreen line.

Monday's report is part of a larger M&A industry push which also includes today's confirmation that Pfizer has been courting—and been refbuffed by—AstraZeneca, as well as Bloomberg's report that Bayer is considering selling its $10 billion plastics division to Evonik Industries AG. Bloomberg said the sale would “whittle down one of Europe's last remaining major pharmaceutical and chemicals conglomerates,” and would coincide with Bayer's push to expand its health and life sciences presence.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.